Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer

Berry, Donald A.; Cirrincione, Constance; Henderson, I. Craig; Citron, Marc L.; Budman, Daniel R.; Goldstein, Lori J.; Martino, Silvana; Perez, Edith A.; Muss, Hyman B.; Norton, Larry; Hudis, Clifford A.; Winer, Eric P.

doi:10.1001/jama.295.14.1658

Cited by 646 publications

(192 citation statements)

References 31 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…Another analysis of three randomized trials involving 6644 women with node positive breast cancer and variable hormone receptor status demonstrated that women with ER-negative breast cancer had a larger reduction in the risk of recurrence compared to women with ER-positive breast cancer at 5 years, (55% vs 26%, respectively). There was also a higher absolute improvement in DFS (23% vs 7%) and higher absolute improvement in OS (17% vs 4 %) [19] .…”

Section: Data Supporting Adjuvant Therapy With Anthracyclinesmentioning

confidence: 84%

“…These results suggest standard dosing anthracycline regimens are equal to CMF but slightly inferior to regimens including higher cumulative doses of anthracyclines, i.e., 6 cycles of an anthracyclinebased regimen being better than 4 cycles. No single regimen has been defined as the absolute gold standard treatment but based on well conducted prospective trials and meta-analyses conducted by the EBCTCG, anthracyclinebased regimens have been recommended for more than 2 decades [17][18][19] . The 2011 EBCTCG meta-analysis also included taxanes such as docetaxel and paclitaxel in its analysis of adjuvant therapy.…”

Section: Data Supporting Adjuvant Therapy With Anthracyclinesmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

Crozier

Swaika

Moreno-Aspitia

2014

WJCO

View full text Add to dashboard Cite

Breast cancer continues to be one of the leading causes of cancer mortality in the world. The treatment generally involves multiple modalities including surgery, radiation and/or chemotherapy. Anthracyclines, one of the first chemotherapeutic agents introduced in the 1960s, has been the backbone for the last 30 years and has been used extensively so far. However, the cardiac toxicity and the concern for secondary hematological malignancy has always been a challenge. A better understanding of the tumor biology, role of Her2 expression and the discovery of trastuzumab and other anti-Her 2 agents along with other effective novel therapeutic options, have revolutionized the treatment for breast cancer. The role of anthracyclines has come under close scrutiny, especially in the adjuvant setting for patients with early stage breast cancer and those with low or intermediate risk of disease recurrence. Recent studies have highlighted such a shift in the use of anthracyclines in both the academic and community clinical practice. However, in patients with a high risk of relapse, anthracyclines still hold promise. Ongoing clinical trials are underway to further define the role of anthracyclines in such a patient population. This review highlights the development, clinical utility, limitations and potential future use of anthracyclines in the adjuvant setting for patients with breast cancer. We consulted PubMed, Scopus, MEDLINE, ASCO annual symposium abstracts, and http://clinicaltrials.gov/ for the purpose of this review. Crozier JA, Swaika A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.

show abstract

Section: Data Supporting Adjuvant Therapy With Anthracyclinesmentioning

confidence: 84%

Section: Data Supporting Adjuvant Therapy With Anthracyclinesmentioning

confidence: 99%

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

Crozier

Swaika

Moreno-Aspitia

2014

WJCO

View full text Add to dashboard Cite

show abstract

“…The standard therapeutic protocol for ER-negative breast cancer is limited; therefore better drugs are very much in need. [31][32][33] Our results suggest that compound 1, the derivative most similar to mithramycin (only the 3E-methyl group is missing), significantly induced apoptosis in both the ER + MCF-7 and the ER -MDA 231 cells when compared to mithramycin. Thus, this compound may serve as an effective therapeutic aid in the management of breast cancer.…”

Section: Resultsmentioning

confidence: 99%

Mithramycin Analogues Generated by Combinatorial Biosynthesis Show Improved Bioactivity

et al. 2008

View full text Add to dashboard Cite

Plasmid pLNBIV was used to overexpress the biosynthetic pathway of nucleoside-diphosphate (NDP)-activatedL-digitoxose in the mithramycin producer Streptomyces argillaceus. This led to a "flooding" of the biosynthetic pathway of the antitumor drug mithramycin (MTM) with NDPactivated deoxysugars, which do not normally occur in the pathway, and consequently to the production of the four new mithramycin derivatives 1-4 with altered saccharide patterns. Their structures reflect that NDP sugars produced by pLNBIV, namely, L-digitoxose and its biosynthetic intermediates, influenced the glycosyl transfer to positions B, D, and E, while positions A and C remained unaffected. All four new structures have unique, previously not found sugar decoration patterns, which arise from either overcoming the substrate specificity or inhibition of certain glycosyltransferases (GTs) of the MTM pathway with the foreign NDP sugars expressed by pLNBIV. An apoptosis TUNEL (=terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) assay revealed that compounds 1 (demycarosyl-3D-β-D-digitoxosyl-MTM) and 3 (deoliosyl-3C-β-Dmycarosyl-MTM) show improved activity (64.8 ± 2% and 50.3 ± 2.5% induction of apoptosis, respectively) against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7 compared with the parent drug MTM (37.8 ± 2.5% induction of apoptosis). In addition, compounds 1 and 4 (3A-deolivosyl-MTM) show significant effects on the ER-negative human breast cancer cell line MDA-231 (63.6 ± 2% and 12.6 ± 2.5% induction of apoptosis, respectively), which is not inhibited by the parent drug MTM itself (2.6 ± 1.5% induction of apoptosis), but for which chemotherapeutic agents are urgently needed.Mithramycin (MTM), a clinically used aureolic acid-type anti-cancer drug and calciumlowering agent produced by Streptomyces argillaceus as well as various other streptomycetes, consists of a polyketide-derived tricyclic core with a highly functionalized pentyl side chain at the 3-position and five deoxysugars linked as trisaccharide and disaccharide chains in the 2-and 6-positions, respectively. Its aglycon including the 3-side chain is biosynthesized from 10 acyl-CoA units by a type II polyketide synthase, and all five deoxyhexose moieties are successively attached to the tetracyclic intermediate premithramycinone, resulting in the fully glycosylated intermediate premithramycin B via premithramycin A 3 , 1-7 before an oxidative cleavage reaction, catalyzed by Baeyer-Villigerase MtmOIV, 3,5,7 followed by the reduction of a side chain keto group by MtmW, finishes the biosynthesis (Scheme 1). The glycosylation Since genes for only four GTs were found in the mtm gene cluster, which are responsible for five glycosylation steps, it was suggested from indirect evidence 8 that MtmGIV catalyzes the attachment of both sugars C (proven) and E (likely), while MtmGIII catalyzes the attachment of oliose D. MtmGI and MtmGII are responsible for the attachment of olivoses A and B, respectively. It is well-known that the glycos...

show abstract

“…Indeed. The problem is that although we are learning rapidly about the biology of breast cancer and its impact on treatment (Bazell, 1998;Paik et al, 2004Paik et al, , 2006Berry et al, 2006a;Hayes et al, 2007), our understanding is not yet sufficiently advanced to make clear which tumours need treatment, or which treatments are best for which biological subtypes. Nor do we know the proportion of patients in either detection category who will benefit from treatment.…”

mentioning

confidence: 99%

The screening mammography paradox: better when found, perhaps better not to find

Berry

2008

Br J Cancer

View full text Add to dashboard Cite

Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer

Abstract: Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.

Cited by 646 publications

References 31 publications

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

Mithramycin Analogues Generated by Combinatorial Biosynthesis Show Improved Bioactivity

The screening mammography paradox: better when found, perhaps better not to find

Contact Info

Product

Resources

About